PharmiWeb.com - Global Pharma News & Resources
19-Oct-2018

Mucin 1 - Pipeline Review, H2 2018 - ResearchAndMarkets.com

The "Mucin 1 - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive information on the Mucin 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mucin 1 targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
  • The report provides a snapshot of the global therapeutic landscape for Mucin 1
  • The report reviews Mucin 1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mucin 1 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mucin 1 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mucin 1 targeted therapeutics

Companies Featured

  • Akshaya Bio Inc.
  • Bavarian Nordic A/S
  • Bioleaders Corp.
  • Boehringer Ingelheim GmbH
  • Etubics Corp.
  • GeoVax Labs Inc.
  • Merck KGaA
  • Minerva Biotechnologies Corp.
  • NantKwest Inc.
  • Peptron Inc.
  • Transgene SA
  • Vaxil Bio Therapeutics Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wncxng/mucin_1?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005431/en/

Editor Details

Last Updated: 19-Oct-2018